What is recommended for the treatment of chronic kidney disease in a primary care setting?

The recommended treatment for chronic kidney disease (CKD) in a primary care setting includes the use of atorvastatin and SGLT2 inhibitors. Atorvastatin, a statin medication, is effective in managing cholesterol levels, which is crucial for patients with CKD as they have an increased risk of cardiovascular disease. SGLT2 inhibitors help in managing blood glucose levels, particularly in patients with diabetes, and have also been shown to provide renal protective effects by reducing progression to end-stage kidney disease and lowering the risk of hospitalization for heart failure.

In contrast, while calcium supplements may be considered in specific scenarios related to mineral balance, particularly in patients with secondary hyperparathyroidism, they are not a standard treatment for CKD itself. Similarly, increased dietary protein intake is not typically recommended because it can exacerbate kidney function decline. Diuretics may be used to manage fluid overload in CKD patients but are not recommended as a primary treatment strategy for the condition itself. Hence, the combination of atorvastatin and SGLT2 inhibitors aligns with current guidelines for managing CKD, emphasizing cardiovascular health and renal protection.